Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by StevenBirchon Mar 17, 2022 2:52pm
163 Views
Post# 34522852

RE:Breakout Close By

RE:Breakout Close ByI don't think it is a delay, it seems they have moved away from the quarterly update and it's better for the short term price. And we don't need a news release just to tell us that there will no longer be a quarterly update. 

There is no lack of transparency and if anything the 'delay' could be seen as a positive, that just reporting interim results again is a waste when maybe by waiting a little longer there could be real news to report.

Let's be happy, for now anyways, that no one is trying to manipulate the price when news or a halt could catch them off guard. Right now there is only great anticipation in the stock price and that's a good thing.


consultant99 wrote: The chart looks very promising with what appears to be a continuation pattern well formed and just waiting for a small uptic to signal a breakout. The MACD graph also appears to be bottoming and also close to signaling a buy. 

The chart suggests the next move higher will take the stock price into the mid to high 0.50s. 

As an investor I am disappointed with the company in not following through on the quarterly newsletters. This is not a good practice. If they want to do things differently so be it, but there is a responsibility to shareholders to be more transparent in my humble opinion. 

That said I believe in the technology.

Further it is encouraging that while waiting the share price is rising for a change.

But that doesn't excuse the lack of transparency when the company is getting potentially very close to qualifying for BTD and commercialization based on the phase 2 trial.

The right results will,send the share price significantly higher and if they have run into another unexpected problem significantly lower.

Its not that some of us haven't been patient waiting.
Would it hurt to explain the delay?


<< Previous
Bullboard Posts
Next >>